Treatment of spasticity in cerebral palsy with botulinum toxin;Tratamiento de la espasticidad en parálisis cerebral con toxina botulínica

Revista de Neurologia

Volumn 34, Issue 1, 2002, Pages 52-59

  Calderon Gonzalez R ^a   Calderon Sepulveda R F ^a  

^a Ctro Neurologico para Ninos y Adol   (Mexico)

Author keywords

Assessment scales; Botulinum toxin; Cerebral palsy; Muscle contracture; Spasticity

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN B; BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

CEREBRAL PALSY; CHILD; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; GAIT; HUMAN; JOINT MOBILITY; MOTOR PERFORMANCE; MUSCLE CONTRACTURE; MUSCLE LENGTH; MUSCLE SPASM; MUSCLE TONE; PAIN ASSESSMENT; SARCOMERE; SPASTICITY; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOTHERAPY; REVIEW; SKELETAL MUSCLE;

BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; HUMANS; MUSCLE SPASTICITY; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS; PHYSICAL THERAPY MODALITIES;

EID: 0036024063     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3401.2001297     Document Type: Conference Paper

References (62)

1. The changing panorama of cerebral palsy-bilateral spastic forms in particular
2. Spasticity
3. Scientific basis of spasticity: Insights from a laboratory model
4. Spasticity: A review
5. Determinants of muscle function in the spastic lower extremity
6. Longitudinal growth of striated muscle fibers
7. Sarcomere length during post-natal growth of mammalian muscle fibers
8. The relationship between sarcomere length in the soleus and tibialis anterior and the articular angle of the tibia-calcaneum in cats during growth
9. Muscle growth in normal and spastic mice
10. The respective roles of muscle length and muscle tension in sarcomere number adaptation of guinea pigs soleus muscle
11. The effect of immobilization on the longitudinal growth of striated muscle fibers
12. Mechanisms of muscle growth related to muscle contracture in cerebral palsy
13. Muscle fiber and connective tissue changes associated with use and disuse
14. Contractures and their therapy
15. Muscle hyperextensibility in children with cerebral palsy. I. Clinical and experimental observations
16. For how long must the soleus muscle be stretched each day to prevent contracture?
17. Studies of spasticity in man. I. Some features of spasticity
18. Studies of spasticity in man. 2. Analysis of streatch reflexes in spasticity
19. Studies of spasticity in man. 3. Analysis of reflex activity evoked by noxious cutaneous stimulation
20. Clinical considerations in cerebral palsy and spasticity
21. The effect of a weight-bearing physical activity program on bone mineral content and estimated volumetric density in children with spastic cerebral palsy
22. Gait assessment of fixed ankle-foot orthoses in children with spastic diplegia
23. A preliminary evaluation of ankle orthoses in the management of children with cerebral palsy
24. Fisiopatología de la espasticidad y papel de la toxina botulínica en su tratamiento
25. Reflex excitability and isometric force production in cerebral palsy: The effect of serial casting
26. Muscle response to heavy resistance exercise in children with spastic cerebral palsy
27. Preliminary trial of carisoprodol in multiple sclerosis
28. Interrater reliability of a modified Ashworth scale of muscle spasticity
29. Objective measurement of clinical findings in the use of botulinum toxin type A for management of children with cerebral palsy
30. A la recherche d'une technique de mesure de la spasticite
31. Treatment of spasticity with botulinum toxin: A double-blind study
32. Development and reliability of a system to classify gross motor function in children with cerebral palsy
33. Reliability and validity of the Pediatric Evaluation of Disability Inventory
34. Use of functional assessment in children with developmental disabilities
35. Quantifying the effects of interventions for movement disorders resulting from cerebral palsy
36. Historical aspects of botulinum toxin: Justinus Kemer (1786-1862) and the sausage poison
37. Pharmacologic weakening of extraocular muscles
38. From the Foods and Drug Administration
39. Clinical utility of botulinum toxin in the treatment of cerebral palsy: Comprehensive review
40. The therapeutic uses of botulinum toxins
41. Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology
42. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dystonia, other focal dystonias and hemifacial spasm
43. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals
44. Experimental botulism in monkeys: A clinical pathological study
45. Spasticity management: An overview
46. Response to immunoresistance to botulinum toxin injections
47. Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse
48. Management of cerebral palsy with botulinum-A toxin: Preliminary investigation
49. Botulinum toxin A in the management of cerebral palsy
50. Botulinum toxin in the management of the lower limb in cerebral palsy
51. Injection of botulinum toxin A into the gastrocnemius muscle of patients with cerebral palsy: A 3-dimentional motion analysis study
52. Botulinum toxin A compared with stretching casts in the treatment of spastic equines: A randomized prospective trial
53. The effect of botulinum toxin A on gastrocnemius muscle length: Magnitude and duration of response
54. The use of botulinum toxin type A in children with cerebral palsy: A retrospective study
55. Adductor spasticity in children with cerebral palsy and treatment with botulinum toxin type A: The parent's view of functional outcome
56. Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy
57. Management of spasticity in cerebral palsy with botulinum-A toxin: Report of a preliminary, randomized, double blind trial
58. Botulinum toxin A in the hemiplegic upper limb: A double-blind trial
59. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle of patients with cerebral palsy
60. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: A randomized, double-blind, placebo-controlled trial